{"entity": "journal", "iuid": "c02fea7199594d4fa21a05618dc57b80", "timestamp": "2026-07-20T22:38:36.119Z", "links": {"self": {"href": "https://publications.scilifelab.se/journal/Eur.%20J.%20Neurol..json"}, "display": {"href": "https://publications.scilifelab.se/journal/Eur.%20J.%20Neurol."}}, "title": "Eur. J. Neurol.", "issn": "1468-1331", "issn-l": "1351-5101", "publications_count": 4, "publications": [{"entity": "publication", "iuid": "9de5d70a240743dd9a671e5e9fe20877", "links": {"self": {"href": "https://publications.scilifelab.se/publication/9de5d70a240743dd9a671e5e9fe20877.json"}, "display": {"href": "https://publications.scilifelab.se/publication/9de5d70a240743dd9a671e5e9fe20877"}}, "title": "B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.", "authors": [{"family": "Asplund H\u00f6gelin", "given": "Klara", "initials": "K", "orcid": "0000-0002-3696-355X", "researcher": {"href": "https://publications.scilifelab.se/researcher/7a0642ad3dcd48bcb32acac944de9c31.json"}}, {"family": "Ruffin", "given": "Nicolas", "initials": "N"}, {"family": "Pin", "given": "Elisa", "initials": "E"}, {"family": "Hober", "given": "Sophia", "initials": "S"}, {"family": "Nilsson", "given": "Peter", "initials": "P"}, {"family": "Starvaggi Cucuzza", "given": "Chiara", "initials": "C"}, {"family": "Khademi", "given": "Mohsen", "initials": "M"}, {"family": "Olsson", "given": "Tomas", "initials": "T"}, {"family": "Piehl", "given": "Fredrik", "initials": "F"}, {"family": "Al Nimer", "given": "Faiez", "initials": "F"}], "type": "journal article", "published": "2022-07-08", "journal": {"title": "Eur. J. Neurol.", "issn": "1468-1331", "issn-l": "1351-5101"}, "abstract": "Recent findings document a blunted humoral response to SARS-CoV-2 vaccination in patients on anti-CD20 treatment. Although most patients develop a cellular response, it is still important to identify predictors of seroconversion to optimize vaccine responses.\n\nWe determined antibody responses after SARS-CoV-2 vaccination in a real-world cohort of multiple sclerosis patients (n = 94) treated with anti-CD20, mainly rituximab, with variable treatment duration (median = 2.9, range = 0.4-9.6 years) and time from last anti-CD20 infusion to vaccination (median = 190, range = 60-1032 days).\n\nWe find that presence of B cells and/or rituximab in blood predict seroconversion better than time since last infusion. Using multiple logistic regression, presence of >0.5% B cells increased probability of seroconversion with an odds ratio (OR) of 5.0 (95% confidence interval [CI] = 1.0-28.1, p = 0.055), whereas the corresponding OR for \u22656 months since last infusion was 1.45 (95% CI = 0.20-10.15, p = 0.705). In contrast, detectable rituximab levels were negatively associated with seroconversion (OR = 0.05, 95% CI = 0.002-0.392, p = 0.012). Furthermore, na\u00efve and memory IgG+ B cells correlated with antibody levels. Although retreatment with rituximab at 4 weeks or more after booster depleted spike-specific B cells, it did not noticeably affect the rate of decline in antibody titers. Interferon-\u03b3 and/or interleukin-13 T-cell responses to the spike S1 domain were observed in most patients, but with no correlation to spike antibody levels.\n\nThese findings are relevant for providing individualized guidance to patients and planning of vaccination schemes, in turn optimizing benefit-risk with anti-CD20.", "doi": "10.1111/ene.15492", "pmid": "35808856", "labels": {"Autoimmunity and Serology Profiling": "Collaborative"}, "xrefs": [{"db": "pmc", "key": "PMC9349816"}], "notes": [], "created": "2022-08-08T12:57:24.608Z", "modified": "2022-08-08T12:57:24.673Z"}, {"entity": "publication", "iuid": "d85f62c78d2044ef9004017e2fc70aa4", "links": {"self": {"href": "https://publications.scilifelab.se/publication/d85f62c78d2044ef9004017e2fc70aa4.json"}, "display": {"href": "https://publications.scilifelab.se/publication/d85f62c78d2044ef9004017e2fc70aa4"}}, "title": "Fibroblast growth factor 23 is associated with risk of intracerebral hemorrhage.", "authors": [{"family": "Svensson", "given": "Edith H", "initials": "EH", "orcid": "0000-0001-7720-3701", "researcher": {"href": "https://publications.scilifelab.se/researcher/5bacb475dc8448d68e2be43f26e7a02a.json"}}, {"family": "S\u00f6derholm", "given": "Martin", "initials": "M"}], "type": "journal article", "published": "2022-01-00", "journal": {"title": "Eur. J. Neurol.", "issn": "1468-1331", "volume": "29", "issue": "1", "pages": "114-120", "issn-l": "1351-5101"}, "abstract": "Fibroblast growth factor 23 (FGF23) is an osteogenic hormone associated with chronic kidney disease and is an emerging risk factor for several cardiovascular diseases. The association of FGF23 with stroke is unclear. The aim of this study was to investigate the association of FGF23 with incident intracerebral hemorrhage (ICH).\n\nThis was a nested case-control study of 220 ICH cases and 244 age- and sex-matched controls from the population-based Malm\u00f6 Diet and Cancer Study (n = 28,449). Incident ICH cases were ascertained using national registers and classified by bleeding location. Logistic regression was used to study the association of plasma levels of FGF23 with incident ICH, adjusting for potential ICH risk factors. Subgroup analyses were performed for lobar and non-lobar ICH, fatal ICH, ICH with large volume and ICH with poor functional outcome, respectively.\n\nHigher FGF23 levels at baseline were significantly associated with incident ICH. After multivariable adjustment, the odds ratio for the association with all ICH was 1.84 (95% confidence interval [CI] 1.25-2.71, p = 0.002) per doubling of FGF23 concentration. For lobar and non-lobar ICH, odds ratios were 1.73 (95% CI 1.04-2.87, p = 0.035) and 2.13 (95% CI 1.32-3.45, p = 0.002), respectively. FGF23 was also significantly associated with fatal ICH, ICH with large volume and ICH with poor functional outcome.\n\nHigher FGF23 was associated with incident ICH in this nested case-control study. Further studies are required to explore whether the association is causal.", "doi": "10.1111/ene.15060", "pmid": "34379844", "labels": {"Affinity Proteomics Uppsala": "Service"}, "xrefs": [], "notes": [], "created": "2021-12-10T09:10:06.377Z", "modified": "2022-12-02T09:01:06.950Z"}, {"entity": "publication", "iuid": "3e31cf6c2c144c12ae03f5f06cc3c661", "links": {"self": {"href": "https://publications.scilifelab.se/publication/3e31cf6c2c144c12ae03f5f06cc3c661.json"}, "display": {"href": "https://publications.scilifelab.se/publication/3e31cf6c2c144c12ae03f5f06cc3c661"}}, "title": "Genetic variation in complement component C3 shows association with ischaemic stroke.", "authors": [{"family": "Olsson", "given": "S", "initials": "S"}, {"family": "Stokowska", "given": "A", "initials": "A"}, {"family": "Holmegaard", "given": "L", "initials": "L"}, {"family": "Jood", "given": "K", "initials": "K"}, {"family": "Blomstrand", "given": "C", "initials": "C"}, {"family": "Pekna", "given": "M", "initials": "M"}, {"family": "Jern", "given": "C", "initials": "C"}], "type": "journal article", "published": "2011-10-00", "journal": {"volume": "18", "issn": "1468-1331", "issue": "10", "pages": "1272-1274", "title": "Eur. J. Neurol.", "issn-l": "1351-5101"}, "abstract": "The aim of this study was to investigate whether genetic variation at the third complement component (C3) locus is associated with ischaemic stroke (IS).\n\nThe Sahlgrenska Academy Study on Ischaemic Stroke comprises 844 patients with IS, and 668 healthy controls. Sixteen SNPs were analyzed.\n\nTwo SNPs, rs2277984 and rs3745565, showed a significant association with overall IS. The SNP rs2277984 also showed association with the IS subtype cryptogenic stroke. These associations were independent of hypertension, diabetes, and smoking. The independent association between rs3745565 and overall IS withstands correction for multiple testing.\n\nIn this sample of patients with IS, genetic variation in C3 is associated with IS.", "doi": "10.1111/j.1468-1331.2011.03377.x", "pmid": "21414106", "labels": {"National Genomics Infrastructure": null, "NGI Uppsala (SNP&SEQ Technology Platform)": null}, "xrefs": [], "notes": [], "created": "2017-05-04T15:00:43.673Z", "modified": "2020-01-21T13:56:01.776Z"}, {"entity": "publication", "iuid": "ffda3b19c8eb4e6c84f82b2ef8d35ffb", "links": {"self": {"href": "https://publications.scilifelab.se/publication/ffda3b19c8eb4e6c84f82b2ef8d35ffb.json"}, "display": {"href": "https://publications.scilifelab.se/publication/ffda3b19c8eb4e6c84f82b2ef8d35ffb"}}, "title": "Genetic variation on chromosome 9p21 shows association with the ischaemic stroke subtype large-vessel disease in a Swedish sample aged \u2264 70.", "authors": [{"family": "Olsson", "given": "S", "initials": "S"}, {"family": "Jood", "given": "K", "initials": "K"}, {"family": "Blomstrand", "given": "C", "initials": "C"}, {"family": "Jern", "given": "C", "initials": "C"}], "type": "journal article", "published": "2011-02-00", "journal": {"volume": "18", "issn": "1468-1331", "issue": "2", "pages": "365-367", "title": "Eur. J. Neurol.", "issn-l": "1351-5101"}, "abstract": "The aim of this study was to investigate whether we could replicate a recent finding of an association between genetic variants on chromosome 9p21 and the ischaemic stroke (IS) subtype large-vessel disease (LVD).\n\nThe Sahlgrenska Academy Study on Ischemic Stroke comprises 844 patients with IS, who suffered IS before reaching the age of 70, and 668 healthy controls. IS subtype was defined according to the TOAST criteria, and 111 patients were categorized as LVD. Seven single-nucleotide polymorphisms (SNPs) on 9p21 were analyzed. Functional outcome was assessed 3 months after IS using the modified Rankin scale.\n\nThe SNP rs7857345 showed a significant association with the subtype LVD independent of traditional vascular risk factors. In addition, an association between rs7857345 and functional outcome after LVD was observed.\n\nIn this relatively young sample of patients with IS, genetic variation on 9p21 is associated with LVD.", "doi": "10.1111/j.1468-1331.2010.03096.x", "pmid": "20500804", "labels": {"National Genomics Infrastructure": null, "NGI Uppsala (SNP&SEQ Technology Platform)": null}, "xrefs": [{"db": "pii", "key": "ENE3096"}], "notes": [], "created": "2017-05-04T15:00:43.345Z", "modified": "2020-01-21T13:56:06.549Z"}], "created": "2017-05-09T09:12:43.405Z", "modified": "2020-11-27T13:14:03.179Z"}